Summary: As GLP-1 medications such as Ozempic and Wegovy gain popularity for weight management, new research highlights a growing social backlash. A study from Georgetown University Medical Center finds that women who lose weight with GLP-1 drugs face stronger stigma than those who lose weight through diet and exercise. Much of that stigma stems from the belief that medication-assisted weight loss is an “easy way out,” a perception that—surprisingly—was stronger when the person using the medication was portrayed as white.
Key Findings
- Racial differences in stigma: Contrary to expectations, participants expressed greater stigma when the vignette depicted a white woman rather than a Black woman using a GLP-1 medication. White women in the scenarios were more likely to be accused of taking a “shortcut,” which translated into higher social rejection.
- Shared perceptions across participants: The race of the study participants themselves did not change the primary outcome—both Black and white respondents were similarly likely to view GLP-1 use as a shortcut.
- Widespread use: About 18% of U.S. adults have used or currently use a GLP-1 drug for weight loss, while over 100 million Americans are clinically eligible for these medications.
- Clinical consequences of stigma: Weight-related stigma is associated with stress, depression, anxiety, and unhealthy coping behaviors; it can also deter people who could benefit from evidence-based treatments from seeking care.
The study, published April 9 in the American Psychological Association’s journal Stigma & Health, examined how social narratives about weight loss shape attitudes toward women with obesity. Researchers found that negative reactions to medication-assisted weight loss were largely driven by beliefs that the drug-assisted approach represented an unfair or morally dubious shortcut compared with diet and exercise.
Researchers recruited 402 U.S. women aged 30 to 49 who identified as Black or white and who self-reported overweight or obesity. Each participant was randomly assigned to read a short vignette about a woman named Evette who lost 15% of her body weight either through diet and exercise or with a GLP-1 medication. Evette was shown as either Black or white using pre-tested photos to avoid perceptual differences. Participants then rated Evette on measures that included fat phobia, dislike, blame, and desire for social distance, and reported whether they believed she had taken a weight loss “shortcut.”
Across measures, stigma was higher when weight loss was attributed to a GLP-1 medication versus lifestyle changes. The belief that medication represented a shortcut was a consistent mediator: endorsing that belief predicted higher levels of fat phobia, greater dislike, increased blame, and stronger desire to keep social distance. Unexpectedly, these shortcut beliefs and the resulting stigma were more likely when the woman in the vignette was portrayed as white.
Lead author Stacy Post, PhD, a social psychologist at Georgetown’s Lombardi Comprehensive Cancer Center, notes that GLP-1 medications can provide meaningful health benefits for people with obesity, yet many patients report shame and guilt for using them. The study suggests that stigma goes beyond casual criticism and can produce measurable negative attitudes that harm mental and physical well-being.
Weight stigma is linked to adverse health outcomes, including elevated stress, worsening depression and anxiety symptoms, and unhealthy behaviors that undermine long-term health. The authors warn that stigma surrounding GLP-1 medications could discourage people who are clinically eligible from seeking or adhering to effective treatment, and could intensify shame for those already managing chronic conditions.
To reduce stigma, the researchers recommend public communication that explains the biological mechanisms behind GLP-1 medications, emphasizes health outcomes rather than appearance, and reframes weight management away from moralized ideas of willpower. Changing the narrative from “willpower” to “biology” may help reduce the perception that medication-assisted weight loss is inherently less legitimate than lifestyle approaches.
Key Questions Answered:
A: The study suggests participants were more likely to attribute a “shortcut” motive when the vignette featured a white woman. That shortcut belief predicted higher dislike and blame, which increased overall stigma.
A: Yes. Feeling shamed can stop patients from continuing medication, seeking medical advice, or engaging in other beneficial care. Shame and social rejection can worsen mental health and reduce the likelihood of sustained, positive health behavior.
A: The researchers advocate reframing public conversations: explain how GLP-1s work, focus on measurable health benefits, and decouple weight loss methods from moral judgments. This approach aims to validate multiple, evidence-based paths to improved health.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by staff.
- Additional context was added by editorial staff to clarify implications.
About this weight loss and psychology research news
Author: Karen Teber
Source: Georgetown University Medical Center
Contact: Karen Teber – Georgetown University Medical Center
Image: The image is credited to Neuroscience News
Original Research: Closed access. “Social Perceptions of GLP-1–assisted Weight Loss in Black and White Women with Obesity” by Post, S. M., Stock, M. L., & Persky, S., published in Stigma and Health. DOI: 10.1037/sah0000689
Abstract
Social Perceptions of GLP-1–assisted Weight Loss in Black and White Women with Obesity
Intersectionality theory suggests stigma results from intersecting social identities, and the researchers initially hypothesized that Black women with obesity might face stronger negative attitudes when using GLP-1 receptor agonists. This experimental study tested how perceived weight loss method (diet/exercise versus GLP-1 medication) and the portrayed race of a woman with obesity affected stigmatizing attitudes among Black and white women with overweight or obesity.
In a randomized vignette design with 402 participants, the woman in the scenario lost 15% of her total body weight either through diet/exercise or with a GLP-1. Participants rated stigmatizing attitudes—fat phobia, dislike, desire for social distance, and blame—and whether they believed the weight loss was a shortcut.
Results showed higher stigma when weight loss was attributed to GLP-1 medication versus lifestyle change, and unexpectedly, greater stigma when the woman was portrayed as white rather than Black. Mediation analysis indicated that shortcut beliefs explained the link between GLP-1–assisted weight loss and increased stigma, with a stronger effect when the vignette depicted a white woman. Participant race did not significantly alter this mediated effect.
These findings underscore the need to challenge societal narratives about “acceptable” weight loss strategies and to communicate more effectively about biological mechanisms and health benefits of evidence-based obesity treatments to reduce stigma and improve access to care.